A Multicenter, Randomized, Open, Parallel Controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs TQF 3510 (Primary) ; Semaglutide
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 26 Dec 2024 New trial record